ERYTECH Pharma completes the enrollment of patients in its Phase I clinical trial in pancreatic cancer Post author:admERY Post published:June 27, 2011 Post category:Newsroom ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. You Might Also Like ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two Upcoming Medical Meetings March 7, 2017 ERYTECH to present at upcoming investor conferences May 20, 2013 ERYTECH reports positive Phase 2b data for eryaspase for the treatment of metastatic pancreatic cancer March 27, 2017
ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two Upcoming Medical Meetings March 7, 2017
ERYTECH reports positive Phase 2b data for eryaspase for the treatment of metastatic pancreatic cancer March 27, 2017